Mitiglinide (INN,[1] trade name Glufast) is a drug for the treatment of type 2 diabetes.

[2] Mitiglinide belongs to the meglitinide (glinide) class of blood glucose-lowering drugs and is currently co-marketed in Japan by Kissei and Takeda.

The North America rights to mitiglinide are held by Elixir Pharmaceuticals.

Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive potassium KATP channels in pancreatic β cells.

Mitiglinide is delivered in tablet form.